Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension
I'm PortAI, I can summarize articles.
Vaxcyte, Inc. (NASDAQ:PCVX) has begun dosing patients in its Phase 3 OPUS trial, evaluating VAX-31 for preventing invasive pneumococcal disease and pneumonia in adults. Wall Street analysts consider it a top biotech stock to buy.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments